We have always been transreligious: An introduction to transreligiosity

The paper is a proposition and exploration of the term ‘transreligiosity’. We argue that transreligiosity is more apt to describe the transgressive character of religiosity, focusing more particularly on the transversality of spaces, symbolic or otherwise, which are created in religious phenomena. We examine the porosity of religious boundaries and, ultimately, propose the term transreligiosity to embrace them, placing emphasis on their transreligious character, while perceiving them as a pivotal fragment of transreligiosity. We take some of Latour’s key concepts on ‘purification’, to argue for the ultimate impossibility of it in the sphere of religiosity. While processes of purification have been powerful through efforts to institutionalize and centralize religiosity, on a vernacular level, this has had a contrary effect. Religious subjects have been distanced from a more direct participation (‘mediation’). Hence, they are constantly creating transreligious instances in order to abolish and transgress those rigid borders.info:eu-repo/semantics/acceptedVersio

Many-body state and dynamic behaviour of the pair-correlation function of a small Bose-Einstein condensate confined in a ring potential

We investigate the many-body state and the static and the dynamic behaviour of the pair-correlation function of a Bose-Einstein condensate with a finite atom number, which is confined in a quasi-one-dimensional toroidal/annular potential, both for repulsive, and for attractive interactions. We link the dynamic pair-correlation function that we evaluate with the problem of quantum time crystals. For weak repulsive interatomic interactions and a finite number of atoms the pair-correlation function shows a periodic temporal behaviour, which disappears in the limit of a large atom number, in agreement with general arguments. Finally we provide some insight into older results of attractive interactions, where the time-crystalline behaviour exists only in the limit of a large atom number.Comment: Revised version, accepted for publicatio

Hysteresis and metastability of Bose-Einstein condensed clouds of atoms confined in ring potentials

We consider a Bose-Einstein condensed cloud of atoms which rotate in a toroidal/annular potential. Assuming one-dimensional motion, we evaluate the critical frequencies associated with the effect of hysteresis and the critical coupling for stability of the persistent currents. We perform these calculations using both the mean-field approximation and the method of numerical diagonalization of the many-body Hamiltonian which includes corrections due to the finiteness of the atom number.Comment: 7 pages, 5 figures, section on experimental relevance added, final versio

Drug-Survival Profiling of Second-Line Biologic Therapy in Rheumatoid Arthritis: Choice of Another TNFi or a Biologic of Different Mode of Action?

OBJECTIVES: Aiming to assess the best choice of second-line therapy between second-line TNF-inhibitor (TNFi) and biologics of different mode of action (BDMA-rituximab/tocilizumab/abatacept) in rheumatoid arthritis (RA) by assessing their drug-survival spanning more that 10years, after discontinuation of the first-line TNFi. METHODS: This retrospective-observational drug-survival study was performed across 2-different hospitals in UK by conventional-statistics and machine-learning approach. RESULTS: From a total of 435-patients, 213 [(48.9%); TNFi-n=122 (57.3%), BDMA-n=91(42.7%)] discontinued their second-line biologic [median-drug-survival: TNFi-27months (95%CI 22-32months) vs BDMA-37months (95%CI 32-52months)]. As second-line, BDMA was likely to reduce the risk of treatment-discontinuation [Hazard-ratio/HR-0.63 (95%CI 0.48-0.83)] compared to TNFi, but only in seropositive-patients [HR-0.52 (95%CI 0.38-0.73)], not in seronegative-RA. Uncovered by the survival-tree and adjusted by propensity-score, drug-survival benefit of BDMA over TNFi was not observed if the seropositive-patients were previously exposed to monoclonal-TNFi (HR-0.77, 95% CI 0.49-1.22) versus soluble TNFi (etanercept or its biosimilar) or if first-line TNFi was terminated within 23.9months of initiation (HR-0.97, 95%CI 0.56-1.68). CONCLUSION: BDMA, as second-line biologic, is more likely to be sustained in seropositive-patients particularly if they were previously not exposed monoclonal TNFi. Drug-survival benefit of BDMA was not observed in seronegative-patients or if the first-line TNFi was stopped within 2 years

Renal cancer and Wegener's granulomatosis: a case report

Wegener's granulomatosis (WG) is a systemic disorder characterized by necrotizing vasculitis involving the respiratory tract, and in most cases, the kidneys. The most common manifestation of WG in the kidneys is segmental necrotizing glomerulonephritis. The presence of a renal mass as a manifestation of WG is rare. We report a patient with WG in whom a CT scan revealed an infiltrating mass in the lower portion of the left kidney. After surgical exploration, we performed an open radical nephrectomy. Histopathology showed clear cell type renal cell carcinoma (RCC). RCC associated with WG has been reported in only a few cases, and in most of them, the diseases started simultaneously, suggesting common pathogenetic pathways. Long-term immunosuppressive treatment is a known risk factor in the development of malignancies, so occurrence of RCC in WG has been proposed as a side effect of cyclophosphamide treatment. Furthermore, it is important to make a differential diagnosis between RCC and pseudotumors in WG as they cannot be distinguished solely on basis of imaging findings. Due to the higher risk of urologic malignancies, more frequent checkups and screening of WG patients should be considered